相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
Solomon A. Graf et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Double Hit and Double Expresser Diffuse Large B Cell Lymphoma Subtypes: Discrete Subtypes and Major Predictors of Overall Survival
Anurag Mehta et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2020)
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
Nagesh Kalakonda et al.
Lancet Haematology (2020)
nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin
Ali G. Saad et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2019)
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy
Daniel J. Landsburg et al.
BLOOD ADVANCES (2019)
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
W. Jurczak et al.
ANNALS OF ONCOLOGY (2018)
Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation
Ichiro Kawashima et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology
David W. Scott et al.
BLOOD (2018)
How I manage patients with relapsed/refractory diffuse large B cell lymphoma
Christian Gisselbrecht et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
Ujjawal H. Gandhi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Management of relapsed/refractory DLBCL
Clementine Sarkozy et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
Double hit and double expressors in lymphoma: Definition and treatment
Peter A. Riedell et al.
CANCER (2018)
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation
Alex F. Herrera et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm
Nara Yoon et al.
ONCOTARGET (2017)
A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib
Allison M. Winter et al.
BLOOD (2017)
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
H. Tilly et al.
ANNALS OF ONCOLOGY (2015)
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
Laurie H. Sehn et al.
BLOOD (2015)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
Y-T Tai et al.
LEUKEMIA (2014)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu et al.
BLOOD (2013)
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation
Julie M. Vose et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276
J. Schmidt et al.
LEUKEMIA (2013)
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
M. Wang et al.
LEUKEMIA (2013)
CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo
Joel G. Turner et al.
JOURNAL OF CANCER (2013)
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
Paul N. Meyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition
Joel G. Turner et al.
CANCER RESEARCH (2009)
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma
Kai Fu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
分享论文
